FDA decision on linvoseltamab in treating RRMM expected in July
The U.S. Food and Drug Administration (FDA) has agreed…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Complete response to CAR T-cell therapy reported in RRMM patient
A first patient with relapsed/refractory multiple myeloma (RRMM)…
Researchers generate plasma cell dataset to aid myeloma diagnosis
Researchers in Brazil have developed a large dataset of…
Sarclisa approved in EU for adults new to MM and transplant ineligible
Regulators in the European Union (EU) have approved…
AbbVie, Simcere Zaiming partner on myeloma treatment SIM0500
Abbvie is teaming up with China-based company…
Under-the-skin Sarclisa found as effective as approved formulation
A subcutaneous, or under-the-skin, formulation of Sarclisa (isatuximab)…
